TYRA News

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology...

August 21, 2025Clinical Trials

Tyra Biosciences Announces Participation at Upcoming Investor Events

TYRA

CARLSBAD, Calif., Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that...

August 20, 2025Investor Events

Piper Sandler Assumes Tyra Biosciences at Overweight, Announces Price Target of $33

TYRA

May 21, 2025

Tyra Biosciences Q1 EPS $(0.47) Beats $(0.48) Estimate

TYRA

May 8, 2025

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

TYRA

March 31, 2025

Tyra Biosciences Q4 2024 GAAP EPS $(0.43) Beats $(0.47) Estimate

TYRA

March 27, 2025

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

TYRA

February 18, 2025

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

TYRA

January 13, 2025

Tyra Biosciences Receives IND Clearance From The FDA To Proceed With A Phase 2 Study Of TYRA-300 In Non-Muscle Invasive Bladder Cancer

TYRA

January 10, 2025